1. Kawasaki T. Acute febrile mucocutaneous syndrome
with lymphoid involvement with specific desquamation of the fingers and
toes in children. Arerugi. 1967;16:178-222.
2. Burns JC. Commentary: translation of Dr Tomisaku
Kawasaki’s original report of fifty patients in 1967. Pediatr Infect Dis
J. 2002;21:993-5.
3. Burns JC, Kushner HI, Bastian JF, Shike H, Shimizu
C, Matsubara T, et al. Kawasaki disease: A brief history.
Pediatrics. 2000;106:e27.
4. Kawasaki T. Pediatric acute febrile mucocutaneous
lymph node syndrome with characteristic desquamation of fingers and
toes: my clinical observation of fifty cases. Pediatr Infect Dis J.
2002;21:1-38.
5. Kato H, Koike S, Yamamoto M, Ito Y, Yano E.
Coronary aneurysms in infants and young children with acute febrile
mucocutaneous lymph node syndrome. J Pediatr. 1975;86:892-8.
6. Tanaka N, Naoe S, Masuda H, Ueno T. Pathological
study of sequelae of Kawasaki disease (MCLS) with special reference to
the heart and coronary arterial lesions. Acta Pathol Jpn.
1986;36:1513-27.
7. Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S,
Aoyama Y, et al. Descriptive epidemiology of Kawasaki disease in
Japan, 2011-2012: From the results of the 22nd nationwide survey. J
Epidemiol. 2015;25:239-45.
8. Singh S, Vignesh P, Burgner D. The epidemiology of
Kawasaki disease: a global update. Arch Dis Child. 2015;100:1084-8.
9. Kim GB, Park S, Eun LY, Han JW, Lee SY, Yoon KL,
et al. Epidemiology and clinical features of Kawasaki disease in
South Korea, 2012-2014. Pediatr Infect Dis J. 2017;36:482-5.
10. Lin MC, Lai MS, Jan SL, Fu YC. Epidemiologic
features of Kawasaki disease in acute stages in Taiwan, 1997-2010:
Effect of different case definitions in claims data analysis. J Chin Med
Assoc. 2015;78:121-6.
11. Du ZD, Zhang T, Liang L, Meng X, Li T, Kawasaki
T, et al. Epidemiologic picture of Kawasaki disease in Beijing
from 1995 through 1999. Pediatr Infect Dis J. 2002;21:103-7.
12. Li X, Li X, Li H, Xu M, Zhou M. Epidemiological
survey of Kawasaki disease in Sichuan province of China. J Trop Pediatr.
2008;54:133-6.
13. Du ZD, Zhao D, Du J, Zhang YL, Lin Y, Liu C,
et al. Epidemiologic study on Kawasaki disease in Beijing from 2000
through 2004. Pediatr Infect Dis J. 2007;26:449-51.
14. Ma X, Yu C, Huang M, Chen S, Huang M, Huang G,
et al. Epidemiologic features of Kawasaki disease in Shanghai from
2003 through 2007. Chin Med J (Engl). 2010;123:2629-34.
15. Chen J-J, Ma X-J, Liu F, Yan W-L, Huang M-R,
Huang M, et al. Epidemiologic features of Kawasaki disease in
Shanghai from 2008 through 2012. Pediatr Infect Dis J. 2016;35:7-12.
16. Singh S, Aulakh R, Bhalla AK, Suri D, Manojkumar
R, Narula N, et al. Is Kawasaki disease incidence rising in
Chandigarh, North India? Arch Dis Child. 2011;96:137-40.
17. Singh S, Bhattad S. Kawasaki disease incidence at
Chandigarh, North India, during 2009-2014. Rheumatol Int.
2016;36:1391-7.
18. Kushner HI, Macnee R, Burns JC. Impressions of
Kawasaki syndrome in India. Indian Pediatr. 2006;43:939-42.
19. Burns JC. Kawasaki Disease update. Indian J
Pediatr. 2009;76:71-6.
20. Kumar RK, Tandon R. Rheumatic fever & rheumatic
heart disease: The last 50 years. Indian J Med Res. 2013;137:643-58.
21. Newburger JW, Takahashi M, Burns JC. Kawasaki
Disease. J Am Coll Cardiol. 2016;67:1738-49.
22. McCrindle BW, Rowley AH, Newburger JW, Burns JC,
Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term
management of Kawasaki disease: A scientific statement for health
professionals from the American Heart Association. Circulation.
2017;135:e927-99.
23. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura
Y, Kiyosawa N, et al. Revision of diagnostic guidelines for
Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47:232-4.
24. Newburger JW, Takahashi M, Gerber MA, Gewitz MH,
Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term
management of Kawasaki disease: a statement for health professionals
from the Committee on Rheumatic Fever, Endocarditis and Kawasaki
Disease, Council on Cardiovascular Disease in the Young, American Heart
Association. Circulation. 2004;110:2747-71.
25. Singh S, Sharma A, Jiao F. Kawasaki Disease:
Issues in diagnosis and treatment—A developing country perspective.
Indian J Pediatr. 2016; 83:140-5.
26. Vijayvergiya R, Bhattad S, Varma S, Singhal M,
Gordon J, Singh S. Presentation of missed childhood Kawasaki disease in
adults: Experience from a tertiary care center in north India. Int J
Rheum Dis. 2017;20:1023-7.
27. Singh S, Agarwal S, Bhattad S, Gupta A, Suri D,
Rawat A, et al. Kawasaki disease in infants below 6 months: A
clinical conundrum? Int J Rheum Dis. 2016;19:924-8.
28. Salgado AP, Ashouri N, Berry EK, Sun X, Jain S,
Burns JC, et al. High risk of coronary artery aneurysms in
infants younger than 6 months of age with Kawasaki disease. J Pediatr.
2017;185:112-6.
29. Singh S, Kawasaki T. Kawasaki disease in India,
lessons learnt over the last 20 years. Indian Pediatr. 2016;53:119-24.
30. Youn Y, Kim J, Hong YM, Sohn S. Infliximab as the
first retreatment in patients with Kawasaki disease resistant to initial
intravenous immunoglobulin. Pediatr Infect Dis J. 2016;35:457-9.
31. Singh S, Sharma D, Suri D, Gupta A, Rawat A,
Rohit MK. Infliximab is the new kid on the block in Kawasaki disease: A
single-centre study over 8 years from North India. Clin Exp Rheumatol.
2016;34:S134-138.
32. Dusser P, Koné-Paut I. IL-1 inhibition may have
an important role in treating refractory Kawasaki disease. Front
Pharmacol. 2017;8:163.
33. Rizk SRY, El Said G, Daniels LB, Burns JC, El
Said H, Sorour KA, et al. Acute myocardial ischemia in adults
secondary to missed Kawasaki disease in childhood. Am J Cardiol.
2015;115:423-7.
34. Waterhouse BR, Tulloh RMR, Kim Y, Creasy W, Adlam
D, Johnson TW. Retrospective study of the impact of unrecognised
Kawasaki disease, coronary aneurysm and ectasia. Int J Cardiol.
2017;248:308-13.
35. Agarwal S, Agrawal DK. Kawasaki disease:
etiopathogenesis and novel treatment strategies. Expert Rev Clin Immunol.
2017;13:24758.